ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

What is the optimal dose of adipose-derived mesenchymal stem cells treatment for knee osteoarthritis? A conventional and network meta-analysis of randomized controlled trials

Huang, Zongyuan*; Zhang, Shuai; Cao, Mingde; Lin, Zhujian; Kong, Ling; Wu, Xin; Guo, Qianshi; Ouyang, Yuxiang; Song, Yancheng*广东药学院
Stem Cell Research & Therapy2023-9-12DOI: 10.1186/s13287-023-03475-5
1被引4阅读
引用收藏
分享

摘要

Background Despite increasing clinical investigations underscoring the efficacy and safety of adipose-derived mesenchymal stem cells (AD-MSCs) therapy in knee osteoarthritis (KOA), no article has recently reviewed the cell dosage. This study aimed to evaluate the efficacy and safety of varying doses of AD-MSCs in treating KOA using conventional and network meta-analysis. @@@ Methods A search of databases in in Chinese and English was performed to identify randomized controlled trials (RCT) on MSCs for knee osteoarthritis from the inception date to May 1, 2022. This study mainly analyzed the efficacy of AD-MSCs in the treatment of KOA, and subgroup analysis was performed on the therapeutic effects of MSCs from different tissues at the same dose. We divided the different cell doses into low, moderate, and high groups, with the corresponding cell doses: (0-25)*10<^>6, (25-50)*10<^>6, and > 50*10<^>6 cells, respectively. We further analyzed the improvement of improvement of the Visual Analog Scale ( VAS) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores and the incidence of adverse events (AEs) after varied dosage injection. @@@ Results A total of 16 literatures were included in this study, of which 8 literatures were about AD-MSCs. Conventional meta-analysis suggests that AD-MSCs can reduce pain and improve function in KOA patients, regardless of the cell doses, up to 12 months of follow-up. The network meta-analysis showed that intra-articular injection of AD-MSCs significantly improved pain and knee function scores in KOA patients compared with the control group at 3, 6, and 12 months. Among the three groups, the high-dose group had the best treatment effect, and the degree of joint pain and dysfunction indicators improved more significantly in the early stage. For adverse events, there was a doseresponse trend that increased with increasing doses. @@@ Conclusions Both cell doses reduced pain and improved knee function in KOA patients. The effect surpassed in the high- dose group than in the moderate-dose, low-dose and control groups. However, adverse events also increase with the increase in dose, which should be carefully considered in clinical application, and the side effects still need to be paid attention to. Considering the limitations of this meta-analysis, future studies need to further explore the efficacy and safety of different doses of treatment, and carry out large sample, multi- center, randomized controlled trials to ensure the reliability and promotion value of the research results.

学科与关键词

关键词
Mesenchymal stem cellsCell dosesKnee osteoarthritisMeta-analysis
相关
加载中…
  • Intra-Articular Mesenchymal Stromal Cell Injections Are No Different From Placebo in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Dai, Wenli; Leng, Xi; Wang, Jian; Shi, Zhanjun; Cheng, Jin; Hu, Xiaoqing*; Ao, Yingfang*Arthroscopy - Journal of Arthroscopic and Related Surgery, 2021, 37(1): 340-358.被引 26
  • Combination of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) in the treatment of knee osteoarthritis: a meta-analysis of randomised controlled trials
    Zhao, Jinlong; Liang, Guihong; Han, Yanhong; Yang, Weiyi; Xu, Nanjun; Luo, Minghui; Pan, Jianke; Liu, Jun*; Zeng, Ling-Feng*BMJ Open, 2022, 12(11): e061008.被引 4
  • Efficacy and cost-effectiveness of Stem Cell injections for symptomatic relief and strUctural improvement in people with Tibiofemoral knee OsteoaRthritis: protocol for a randomised placebo-controlled trial (the SCUlpTOR trial)
    Liu, Xiaoqian; Robbins, Sarah; Wang, Xia; Virk, Sonika; Schuck, Karen; Deveza, Leticia A.; Oo, Win Min; Carmichael, Kirsty; Antony, Benny; Eckstein, Felix; Wirth, Wolfgang; Little, Christopher; Linklater, James; Harris, Anthony; Humphries, David; O'Connell, R.; Heller, Gillian; Buttel, Thomas; Lohmander, Stefan; Ding, Changhai; Hunter, David J.*BMJ Open, 2021, 11(11): e056382.被引 9
查看全部 →

发表信息

论文状态
公开发表
期刊
Stem Cell Research & Therapy
发表日期
2023-09-12
卷期
第 14 卷, 第 1 期
页码
245
DOI
10.1186/s13287-023-03475-5
语言
ENGLISH
成果收录
SCIE
资助标注
Not applicable.

作者

  • H

    Huang, Zongyuan (通讯) (第一作者)

    guangdong pharmaceut univ

  • Z

    Zhang, Shuai

    guangdong pharmaceut univ

查看全部 9 位作者收起作者
  • C

    Cao, Mingde

    chinese univ hong kong

  • L

    Lin, Zhujian

    guangdong pharmaceut univ

  • K

    Kong, Ling

  • W

    Wu, Xin

    guangdong pharmaceut univ

  • G

    Guo, Qianshi

    guangdong pharmaceut univ

  • O

    Ouyang, Yuxiang

    guangdong pharmaceut univ

  • S

    Song, Yancheng (通讯)

    guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417